Børsens News Service in English
Novo Nordisk establishes new type 1 diabetes center
24-01-2012
12:35
Novo Nordisk will establish a research and development center for type 1 diabetes in Seattle in the USA, the pharmaceutical company announced today. Novo Nordisk already operates research facilities in the city as center for its Inflammation Reseach.
The new established research and development center will pursue a translational research approach characterized by combining basic research and early proof-of-concept trials under one umbrella. This will give the new center the necessary scientific foundation to move early-stage discovery projects rapidly from animal models into small clinical exploratory trials in type 1 diabetes.
Novo Nordisk said that in the past decade, type 2 diabetes has been the main focus among diabetes researchers.
The new established research and development center will pursue a translational research approach characterized by combining basic research and early proof-of-concept trials under one umbrella. This will give the new center the necessary scientific foundation to move early-stage discovery projects rapidly from animal models into small clinical exploratory trials in type 1 diabetes.
Novo Nordisk said that in the past decade, type 2 diabetes has been the main focus among diabetes researchers.
Kun for abonnenter
Denne artikel er kun tilgængelig for abonnenter på Børsen.
Log ind på Børsen
*****||*****Novo Nordisk establishes new type 1 diabetes center*****||*****Novo Nordisk will establish a research and development center for type 1 diabetes in Seattle in the USA, the pharmaceutical company announced today. Novo Nordisk already operates research facilities in the city as center for its Inflammation Reseach.*****||*****
News from borsen.dk
